M&S is investigating a potential fraud case regarding the pricing of some of the top-selling insulin drugs, which are used in the treatment of Type 1 and Type 2 diabetes. The manufacturers of many insulin drugs have dramatically increased the list prices of insulin drugs, including Novolog, Humalog, Lantus and Levemir, by over 160% in the last five years.
With the trend towards higher-deductible health plans, including “bronze” and “silver” ACA health plans, many people must pay the full list price for these drugs, or a percentage of the list price. Drug manufacturers insist that the “list price” isn’t the “real” price, but that is the price that millions of people must pay. The prices have gotten so high that some diabetics have no choice but to limit or forgo this essential medicine. M&S would seek to reduce the price of these drugs, and recover damages for individuals who have overpaid.
If you have had to pay high prices for Novolog, Humalog, Lantus or Levemir, please contact us.